As of 6/30/10, the company had a total of $19.1M in cash, cash equivalents and short term investments. Aastrom expects that its cash spending will average approximately $4 – $5 M per quarter over the next 12 months which includes Phase 3 clinical program planning and initiation costs for the critical limb ischemia program.
UT UH,,one year left from last april ? I smell another pipe. Whatcha thinkin JMAC?